Welcome to our dedicated page for Corbus Pharmaceu SEC filings (Ticker: CRBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Corbus Pharmaceuticals Holdings, Inc. (CRBP) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-assisted context for key documents. Corbus is a clinical-stage oncology and obesity company, and its filings reflect the financial, clinical, and governance developments associated with advancing drug candidates such as CRB-701, CRB-601, and CRB-913.
Investors can review Form 8‑K current reports in which Corbus discloses material events, including quarterly financial results, preliminary cash and investment balances, Fast Track designations for CRB-701, and entry into material definitive agreements such as underwriting agreements for public offerings of common stock and pre-funded warrants. Certain 8‑K filings also describe board-level changes, such as the planned retirement of a director, and clarify that such departures are not due to disagreements over company operations or policies.
Quarterly and annual financial information referenced in 8‑K exhibits is complemented by the company’s full 10‑Q and 10‑K reports, which are accessible through EDGAR and summarized by Stock Titan’s AI tools. These reports typically include detailed discussions of research and development spending, net losses associated with clinical-stage operations, and liquidity and capital resources, including the impact of public offerings and at-the-market sales programs.
For users interested in insider and governance activity, Form 4 and related ownership filings, when available, can be used to track changes in beneficial ownership by directors and officers. Stock Titan’s platform surfaces new filings in near real time and applies AI-powered summaries to highlight the sections that matter most, such as clinical program updates, risk factor changes, and financing terms. This allows readers to navigate lengthy SEC documents more efficiently while still being able to drill down into the original filings for full detail.
A holder of Corbus Pharmaceuticals Holdings (symbol CRBP) common stock has filed a notice of proposed sale under Rule 144. The filing covers 20,000 shares of common stock, to be sold through Stifel Nicolaus & Company on the Nasdaq, with an aggregate market value of $812,600. These shares were acquired on February 13, 2026 as restricted stock units granted by the issuer as equity compensation, and became payable on the same date. The notice also confirms the seller states they are not aware of any undisclosed material adverse information about the issuer’s current or future operations.
Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia report a 5.4% beneficial ownership stake in Corbus Pharmaceuticals Holdings, Inc. common stock, representing 955,000 shares. The shares are held by Octagon Investments Master Fund, with Octagon as investment manager and Jia as control person.
The reporting persons share voting and dispositive power over all 955,000 shares and certify that the position was acquired and is held in the ordinary course of business, not for the purpose of changing or influencing control of Corbus Pharmaceuticals.
Corbus Pharmaceuticals’ Chief Medical Officer Dominic Smethurst sold 3,285 shares of common stock on February 3, 2026 at a weighted average price of $8.0898 per share. The shares were sold to cover tax withholding triggered by the vesting and settlement of restricted stock units under an issuer-mandated “sell to cover” arrangement, so the sale was not discretionary. After this transaction, he beneficially owns 95,887 shares, including 86,265 unvested RSUs that remain subject to their vesting schedules.
Corbus Pharmaceuticals Holdings, Inc. Chief Operating Officer Ian Hodgson reported a mandated sale of common stock. On February 3, 2026, he sold 2,415 shares of Corbus common stock at a weighted average price of $8.0899 per share to cover tax withholding from vesting restricted stock units (RSUs).
The company required this "sell to cover" transaction for tax obligations, so it was not a discretionary trade by Hodgson. After the sale, he beneficially owned 51,927 shares, which includes 48,108 unvested RSUs that remain subject to their respective vesting schedules.
Corbus Pharmaceuticals Holdings, Inc.'s Chief Medical Officer, Dominic Smethurst, reported equity awards received on January 14, 2026. He was granted 28,365 restricted stock units (RSUs)85,095 shares at an exercise price of $8.26 per share, vesting 25% on January 14, 2027 and the remaining 75% in equal monthly installments over 36 months starting February 14, 2027. Following these transactions, he beneficially owned 99,172 shares of common stock, including 93,065 unvested RSUs subject to their existing vesting schedules.
Corbus Pharmaceuticals Holdings, Inc. reported an equity compensation grant to its Chief Financial Officer, Sean F. Moran. On January 14, 2026, he received 28,082 restricted stock units (RSUs) that will settle in common stock. These RSUs vest 25% on each of the first four anniversaries beginning January 14, 2027, with a pro rata acceleration feature if the company terminates his service without cause after the first vesting date. Following this grant, he beneficially owns 101,395 shares of common stock, including 85,714 unvested RSUs.
On the same date, he was also granted stock options to purchase 84,247 shares of common stock at an exercise price of $8.26 per share, expiring January 14, 2036. Under the company’s 2024 Equity Compensation Plan, 25% of this option vests on January 14, 2027, with the remaining 75% vesting in equal monthly installments over 36 months starting February 14, 2027.
Corbus Pharmaceuticals Holdings, Inc. CEO Yuval Cohen reported new equity awards. On January 14, 2026, he received 50,000 restricted stock units that will settle in common shares, with 25% vesting on each of the first four anniversaries beginning January 14, 2027. Following this grant, he beneficially owned 188,187 common shares, including 173,561 unvested RSUs subject to their vesting schedules. He was also granted stock options for 150,000 shares at an exercise price of $8.26, expiring January 14, 2036, with 25% vesting on January 14, 2027 and the remaining 75% vesting in equal monthly installments over 36 months starting February 14, 2027.
Corbus Pharmaceuticals Holdings, Inc. reported an equity compensation grant to its Chief Operating Officer, Ian Hodgson. On January 14, 2026, he received 28,365 restricted stock units (RSUs), which will be settled in common shares. These RSUs vest 25% on each of the first four anniversaries beginning January 14, 2027, with a provision for partial accelerated vesting if his service is terminated by the company without cause after the first vesting date.
On the same date, he was also granted 85,095 stock options with a $8.26 exercise price under the 2024 Equity Compensation Plan. Twenty‑five percent of this option vests on January 14, 2027, and the remaining 75% vests in equal monthly installments over 36 months starting February 14, 2027. Following these grants, he beneficially owned 54,342 shares of common stock, which include 53,108 unvested RSUs subject to their respective vesting schedules, and 85,095 options.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported that Aberdeen Group plc and its U.S. affiliate abrdn Inc. have become significant shareholders. The filing shows that these related entities beneficially own a total of 1,321,750 shares of Corbus common stock, representing 7.53% of the outstanding shares as of the reported date. Both Aberdeen Group plc (United Kingdom) and abrdn Inc. (United States) report shared voting and dispositive power over all of these shares, with no sole voting or sole dispositive authority.
The securities are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Corbus, consistent with an institutional investment position under Schedule 13G. The filing notes that abrdn Inc. holds more than 5% of this class of stock on behalf of its underlying clients, with Aberdeen Group plc as the parent company and abrdn Holdings Limited as an intermediate holding company.
Corbus Pharmaceuticals Holdings, Inc. filed a current report to let investors know that management has updated the company’s investor presentation. The revised presentation is being used to describe its business and is furnished as Exhibit 99.1 to the report. The company notes that this material is being provided under a Regulation FD disclosure item, meaning it is intended to share information broadly with the market. The investor presentation and related materials are furnished rather than filed, so they are not automatically subject to certain liability provisions or incorporated into other securities filings unless specifically referenced.
FAQ
What is the current stock price of Corbus Pharmaceu (CRBP)?
What is the market cap of Corbus Pharmaceu (CRBP)?
